Concepts (132)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pneumonia | 5 | 2025 | 60 | 3.040 |
Why?
|
| Pneumonia, Bacterial | 4 | 2025 | 24 | 2.320 |
Why?
|
| Ethanol | 3 | 2025 | 221 | 2.020 |
Why?
|
| Klebsiella Infections | 3 | 2025 | 11 | 1.810 |
Why?
|
| Lung | 5 | 2025 | 484 | 1.790 |
Why?
|
| Klebsiella pneumoniae | 3 | 2025 | 26 | 1.790 |
Why?
|
| Lung Diseases | 2 | 2024 | 62 | 1.010 |
Why?
|
| Uterine Cervical Neoplasms | 5 | 2020 | 350 | 0.890 |
Why?
|
| Cannabinoids | 1 | 2025 | 67 | 0.880 |
Why?
|
| Receptor, Cannabinoid, CB2 | 1 | 2024 | 34 | 0.870 |
Why?
|
| Receptor, Cannabinoid, CB1 | 1 | 2024 | 40 | 0.870 |
Why?
|
| Papillomavirus Infections | 4 | 2020 | 363 | 0.770 |
Why?
|
| Environmental Monitoring | 1 | 2024 | 226 | 0.760 |
Why?
|
| Complex Mixtures | 1 | 2021 | 9 | 0.720 |
Why?
|
| Plague | 3 | 2015 | 25 | 0.680 |
Why?
|
| Yersinia pestis | 3 | 2015 | 35 | 0.670 |
Why?
|
| Mice, Inbred C57BL | 5 | 2025 | 1804 | 0.670 |
Why?
|
| Calcium | 2 | 2021 | 487 | 0.620 |
Why?
|
| Cervix Uteri | 2 | 2018 | 47 | 0.610 |
Why?
|
| Mice | 8 | 2025 | 6490 | 0.600 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2018 | 20 | 0.590 |
Why?
|
| HMGB1 Protein | 1 | 2018 | 30 | 0.580 |
Why?
|
| HIV-1 | 3 | 2015 | 747 | 0.510 |
Why?
|
| Cytokines | 5 | 2025 | 661 | 0.510 |
Why?
|
| Uterine Cervical Dysplasia | 4 | 2020 | 41 | 0.490 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2015 | 10 | 0.460 |
Why?
|
| Macrophages | 3 | 2025 | 515 | 0.460 |
Why?
|
| Interleukin-1beta | 1 | 2015 | 74 | 0.450 |
Why?
|
| Papillomaviridae | 3 | 2020 | 136 | 0.430 |
Why?
|
| env Gene Products, Human Immunodeficiency Virus | 2 | 2015 | 17 | 0.430 |
Why?
|
| Animals | 9 | 2025 | 16695 | 0.410 |
Why?
|
| Disease Models, Animal | 3 | 2025 | 1554 | 0.400 |
Why?
|
| Bronchoalveolar Lavage Fluid | 2 | 2024 | 54 | 0.390 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2011 | 276 | 0.370 |
Why?
|
| Interferon Type I | 1 | 2011 | 18 | 0.360 |
Why?
|
| Thymus Gland | 1 | 2011 | 74 | 0.340 |
Why?
|
| Specimen Handling | 3 | 2020 | 61 | 0.340 |
Why?
|
| Flavoring Agents | 3 | 2025 | 22 | 0.320 |
Why?
|
| Vaginal Smears | 2 | 2020 | 62 | 0.300 |
Why?
|
| Inflammation | 3 | 2024 | 729 | 0.290 |
Why?
|
| North Carolina | 4 | 2023 | 122 | 0.270 |
Why?
|
| Male | 5 | 2025 | 22779 | 0.260 |
Why?
|
| Humans | 16 | 2025 | 42163 | 0.250 |
Why?
|
| Receptors, Cannabinoid | 1 | 2025 | 27 | 0.230 |
Why?
|
| Female | 9 | 2024 | 24018 | 0.220 |
Why?
|
| Air Pollution | 1 | 2024 | 87 | 0.200 |
Why?
|
| Vagina | 2 | 2020 | 89 | 0.190 |
Why?
|
| Lipopolysaccharides | 1 | 2024 | 235 | 0.190 |
Why?
|
| Dendritic Cells | 2 | 2015 | 130 | 0.190 |
Why?
|
| Internship and Residency | 1 | 2023 | 141 | 0.180 |
Why?
|
| Environmental Exposure | 1 | 2024 | 247 | 0.180 |
Why?
|
| Cell Survival | 2 | 2025 | 934 | 0.180 |
Why?
|
| Chemotaxis | 1 | 2021 | 66 | 0.170 |
Why?
|
| Macrophage Activation | 1 | 2021 | 59 | 0.170 |
Why?
|
| Feasibility Studies | 1 | 2022 | 238 | 0.170 |
Why?
|
| Zebrafish | 1 | 2022 | 146 | 0.170 |
Why?
|
| Interleukin-6 | 1 | 2021 | 165 | 0.170 |
Why?
|
| Respiratory Mucosa | 1 | 2020 | 41 | 0.170 |
Why?
|
| Human papillomavirus 16 | 1 | 2020 | 37 | 0.170 |
Why?
|
| DNA, Viral | 2 | 2020 | 323 | 0.170 |
Why?
|
| Cytoplasm | 1 | 2020 | 154 | 0.160 |
Why?
|
| Interferon-gamma | 1 | 2021 | 268 | 0.160 |
Why?
|
| Urinalysis | 1 | 2020 | 34 | 0.160 |
Why?
|
| Calcium Signaling | 1 | 2020 | 108 | 0.160 |
Why?
|
| Patient Preference | 1 | 2020 | 55 | 0.160 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2021 | 379 | 0.150 |
Why?
|
| HIV Infections | 3 | 2023 | 2535 | 0.150 |
Why?
|
| Herpesvirus 4, Human | 1 | 2018 | 36 | 0.150 |
Why?
|
| Disease Progression | 2 | 2018 | 661 | 0.150 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2020 | 471 | 0.140 |
Why?
|
| Cytomegalovirus | 1 | 2018 | 49 | 0.140 |
Why?
|
| Gene Expression | 1 | 2021 | 692 | 0.140 |
Why?
|
| Health Status Disparities | 1 | 2024 | 705 | 0.140 |
Why?
|
| Cell Line | 3 | 2025 | 1416 | 0.130 |
Why?
|
| Epithelial Cells | 1 | 2020 | 426 | 0.130 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2018 | 172 | 0.130 |
Why?
|
| Signal Transduction | 2 | 2024 | 2111 | 0.130 |
Why?
|
| Early Detection of Cancer | 4 | 2020 | 428 | 0.120 |
Why?
|
| Oxidative Stress | 1 | 2021 | 990 | 0.120 |
Why?
|
| nef Gene Products, Human Immunodeficiency Virus | 1 | 2015 | 53 | 0.110 |
Why?
|
| Aged | 4 | 2020 | 7982 | 0.110 |
Why?
|
| Middle Aged | 5 | 2020 | 11819 | 0.110 |
Why?
|
| Neutrophil Infiltration | 1 | 2013 | 28 | 0.100 |
Why?
|
| United States | 1 | 2024 | 5072 | 0.100 |
Why?
|
| Adult | 5 | 2020 | 13458 | 0.100 |
Why?
|
| Neutrophils | 1 | 2013 | 141 | 0.100 |
Why?
|
| Lymphocyte Depletion | 1 | 2011 | 13 | 0.090 |
Why?
|
| Organ Culture Techniques | 1 | 2011 | 102 | 0.090 |
Why?
|
| Herpesvirus 8, Human | 1 | 2010 | 29 | 0.080 |
Why?
|
| Colposcopy | 2 | 2020 | 14 | 0.080 |
Why?
|
| Virus Attachment | 1 | 2009 | 4 | 0.080 |
Why?
|
| HIV Envelope Protein gp41 | 1 | 2009 | 7 | 0.080 |
Why?
|
| Virus Internalization | 1 | 2009 | 36 | 0.080 |
Why?
|
| Receptors, CXCR4 | 1 | 2009 | 74 | 0.080 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2009 | 189 | 0.070 |
Why?
|
| Peripheral Nervous System | 1 | 2025 | 14 | 0.060 |
Why?
|
| Phagocytosis | 1 | 2025 | 83 | 0.060 |
Why?
|
| Central Nervous System | 1 | 2025 | 150 | 0.050 |
Why?
|
| Interferon-alpha | 2 | 2015 | 43 | 0.050 |
Why?
|
| Sensation | 1 | 2022 | 36 | 0.050 |
Why?
|
| Reactive Oxygen Species | 1 | 2025 | 518 | 0.050 |
Why?
|
| Cultural Diversity | 1 | 2023 | 187 | 0.050 |
Why?
|
| Perception | 1 | 2022 | 209 | 0.040 |
Why?
|
| Mentha | 1 | 2020 | 2 | 0.040 |
Why?
|
| Self-Examination | 1 | 2020 | 9 | 0.040 |
Why?
|
| Biopsy | 1 | 2020 | 176 | 0.040 |
Why?
|
| Mycoplasma genitalium | 1 | 2018 | 3 | 0.040 |
Why?
|
| Trichomonas Vaginitis | 1 | 2018 | 5 | 0.040 |
Why?
|
| Mycoplasma Infections | 1 | 2018 | 6 | 0.040 |
Why?
|
| Trichomonas vaginalis | 1 | 2018 | 9 | 0.040 |
Why?
|
| Neisseria gonorrhoeae | 1 | 2018 | 16 | 0.040 |
Why?
|
| Postal Service | 1 | 2018 | 12 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2020 | 438 | 0.040 |
Why?
|
| Gonorrhea | 1 | 2018 | 24 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 1 | 2020 | 454 | 0.040 |
Why?
|
| Chlamydia trachomatis | 1 | 2018 | 69 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2020 | 602 | 0.040 |
Why?
|
| Genotype | 1 | 2020 | 796 | 0.030 |
Why?
|
| Nicotine | 1 | 2020 | 290 | 0.030 |
Why?
|
| Self Care | 1 | 2018 | 173 | 0.030 |
Why?
|
| Chlamydia Infections | 1 | 2018 | 199 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 1058 | 0.030 |
Why?
|
| Biological Warfare Agents | 1 | 2015 | 4 | 0.030 |
Why?
|
| Mass Screening | 1 | 2020 | 531 | 0.030 |
Why?
|
| Virulence | 1 | 2015 | 238 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 1 | 2015 | 427 | 0.030 |
Why?
|
| Apoptosis | 1 | 2020 | 1541 | 0.020 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2010 | 9 | 0.020 |
Why?
|
| Immunoglobulins | 1 | 2010 | 39 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2010 | 122 | 0.020 |
Why?
|
| Membrane Glycoproteins | 1 | 2010 | 221 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2010 | 1617 | 0.020 |
Why?
|